A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Conditions: Inflammatory Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of BreastInterventions: Drug: Eribulin; Drug: Adriamycin; Drug: CyclophosphamideSponsors: Dana-Farber Cancer Institute; Eisai Inc.Not yet recruiting - verified December 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | HER2 | Inflammatory Breast Cancer | Research | Study